Patients will be randomized in a 1:1 ratio to the following monthly treatment groups:~Zimura 2 mg~Sham~At month 12, the patients in the Zimura 2mg treatment group will be re-randomized to receive the study drug either on a monthly basis or on an every other month basis~The patients initially randomized to Sham treatment will continue with monthly Sham injections through Month 23~All patients will have a final follow up visit at Month 24
The objectives of this study are to evaluate the safety and efficacy of Zimura intravitreal administration in patients with geographic atrophy secondary to age-related macular degeneration (AMD)